T008 HHSN26100009 TORFP 2018-E04 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluating Whether a Concurrent Retinoid X Receptor Agonist Can Enhance the Efficacy of HER2-IGFPB2-IGFLR Vaccine in Eliminating Existing Ductal Carcinoma in Situ and Preventing Progression of Invasive Breast Cancer

Grant

Date/time Interval

  • September 15, 2015 - September 16, 2021
  • Total Award Amount

  • 930464.00
  • Direct Costs

  • 883670.00
  • Sponsor Award Id

  • HHSN261201500036I-75N91018F00009
  • Contributor

  • Grubbs Ph.D., Clinton   Principal Investigator